Mukund Paravasthu Sells 5,377 Shares of NovoCure (NASDAQ:NVCR) Stock

Key Points

• COO Mukund Paravasthu sold 48,623 shares over March 4–5 — he disposed of 5,377 shares at $13.31 and 43,246 at $13.77 for roughly $667,065 in proceeds, leaving him with 116,078 shares (~$1.54M).
• Q4 results beat EPS estimates but the company remains unprofitable — NovoCure reported EPS of -$0.22 vs. -$0.41 expected and revenue of $174.35M (up 8.2% YoY), yet it still has a -20.8% net margin and negative ROE.
• Market and analyst outlook is mixed — shares jumped ~6% to $14.23 on the news, the stock has a ~$1.62B market cap, and analysts are split (3 Buy, 3 Hold, 1 Sell) with a consensus target of $26.93.

NovoCure Limited (NASDAQ:NVCR - Get Free Report) COO Mukund Paravasthu sold 5,377 shares of the firm's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total value of $71,567.87. Following the completion of the sale, the chief operating officer directly owned 116,078 shares in the company, valued at approximately $1,544,998.18. The trade was a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Mukund Paravasthu also recently made the following trade(s):

• On Thursday, March 5th, Mukund Paravasthu sold 43,246 shares of NovoCure stock. The shares were sold at an average price of $13.77, for a total transaction of $595,497.42.

NovoCure Trading Up 6.0%

Shares of NVCR stock traded up $0.81 during trading hours on Thursday, hitting $14.23. 2,315,394 shares of the company were exchanged, compared to its average volume of 2,231,897. The firm has a fifty day moving average of $12.73 and a 200 day moving average of $12.70. The company has a quick ratio of 1.50, a current ratio of 2.90 and a debt-to-equity ratio of 0.70. NovoCure Limited has a 1 year low of $9.82 and a 1 year high of $21.55. The firm has a market cap of $1.62 billion, a PE ratio of -11.66 and a beta of 0.71.

NovoCure (NASDAQ:NVCR - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.19. The company had revenue of $174.35 million for the quarter, compared to the consensus estimate of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. NovoCure's revenue was up 8.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.61) earnings per share. Analysts expect that NovoCure Limited will post -1.3 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NVCR. Wedbush reiterated a "neutral" rating and set a $18.00 target price on shares of NovoCure in a report on Thursday, January 15th. Evercore set a $20.00 price objective on shares of NovoCure in a research note on Monday, January 5th. HC Wainwright raised their target price on shares of NovoCure from $47.00 to $49.00 and gave the company a "buy" rating in a research note on Thursday, February 26th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of NovoCure in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $26.93.

Institutional Investors Weigh In On NovoCure

A number of large investors have recently added to or reduced their stakes in the company. Kera Capital Partners Inc. lifted its holdings in NovoCure by 84.4% in the 4th quarter. Kera Capital Partners Inc. now owns 19,691 shares of the medical equipment provider's stock worth $244,000 after buying an additional 9,015 shares in the last quarter. Corient Private Wealth LLC increased its position in shares of NovoCure by 178.0% during the fourth quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider's stock worth $1,259,000 after acquiring an additional 62,341 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its position in shares of NovoCure by 14.5% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider's stock worth $422,000 after acquiring an additional 4,124 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of NovoCure in the fourth quarter worth about $33,000. Finally, XTX Topco Ltd lifted its stake in shares of NovoCure by 159.2% in the fourth quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider's stock worth $760,000 after acquiring an additional 36,111 shares in the last quarter. 84.61% of the stock is owned by institutional investors and hedge funds.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company's non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure's approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.